Role of magnolol in the proliferation of vascular smooth muscle cells;Rolle von Magnolol bei der Proliferation glatter Muskelzellen der Gefäße

Herz

Volumn 40, Issue 3, 2015, Pages 542-548

  Wu, L ^a   Zou, H ^a   Xia, W ^a   Dong, Q ^a   Wang, L ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

ERK1 2; Magnolol; Platelet derived growth factor; Reactive oxygen species; Vascular smooth muscle cells

Indexed keywords

BIPHENYL DERIVATIVE; LIGNAN; MAGNOLOL; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB; REACTIVE OXYGEN METABOLITE;

ANIMAL; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; BIPHENYL COMPOUNDS; CELL PROLIFERATION; CELLS, CULTURED; LIGNANS; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-SIS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

EID: 84894638352     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-014-4051-z     Document Type: Article

References (25)

1. Willis AI, Pierre-Paul D, Sumpio BE, Gahtan V (2004) Vascular smooth muscle cell migration: current research and clinical implications. Vasc Endovascular Surg 38:11–23
2. Greenberg D, Bakhai A, Cohen DJ (2004) Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 43:513–518
3. Moses JW, Leon MB, Popma JJ et al (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323
4. Babapulle MN, Joseph L, Bélisle P et al (2004) A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364:583–591
5. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL (2005) Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 95:1469–1472
6. Nilsen DW, Melberg T, Larsen AI et al (2006) Late complications following the deployment of drug eluting stents. Int J Cardiol 109:398–401
7. Ikeda K, Nagase H (2002) Magnolol has the ability to induce apoptosis in tumor cells. Biol Pharm Bull 25:1546–1549
8. Park J, Lee J, Jung E et al (2004) In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol 496:189–195
9. Lee J, Jung E, Park J et al (2005) Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med 71:338–343
10. Teng CM, Yu SM, Chen CC et al (1990) EDRF-release and Ca+(+)-channel blockade by magnolol, an antiplatelet agent isolated from Chinese herb Magnolia officinalis, in rat thoracic aorta. Life Sci 47:1153–1161
11. Karki R, Ho OM, Kim DW (2013) Magnolol attenuates neointima formation by inducing cell cycle arrest via inhibition of ERK1/2 and NF-kappaB activation in vascular smooth muscle cells. Biochim Biophys Acta 1830:2619–2628
12. Kim HM, Bae SJ, Kim DW et al (2007) Inhibitory role of magnolol on proliferative capacity and matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Int Immunopharmacol 7:1083–1091
13. Luo J, Xu Y, Zhang M et al (2013) Magnolol inhibits LPS-induced inflammatory response in uterine epithelial cells: magnolol inhibits LPS-induced inflammatory response. Inflammation (Epub ahead of print)
14. Jada S, Doma MR, Singh PP et al (2012) Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds. Eur J Med Chem 51:35–41
15. Chen LC, Liu YC, Liang YC et al (2009) Magnolol inhibits human glioblastoma cell proliferation through upregulation of p21/Cip1. J Agric Food Chem 57:7331–7337
16. Chilampalli C, Guillermo R, Zhang X et al (2011) Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action. BMC Cancer 11:456
17. Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677
18. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512
19. Jirawatnotai S, Aziyu A, Osmundson EC et al (2004) Cdk4 is indispensable for postnatal proliferation of the anterior pituitary. J Biol Chem 279:51100–51106
20. Martín A, Odajima J, Hunt SL et al (2005) Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7:591–598
21. Zhao Y, Lv M, Lin H et al (2013) Rho-associated protein kinase isoforms stimulate proliferation of vascular smooth muscle cells through ERK and induction of cyclin D1 and PCNA. Biochem Biophys Res Commun 432:488–493
22. Ravenhall C, Guida E, Harris T et al (2000) The importance of ERK activity in the regulation of cyclin D1 levels and DNA synthesis in human cultured airway smooth muscle. Br J Pharmacol 131:17–28
23. Corona G, Deiana M, Incani A et al (2009) Hydroxytyrosol inhibits the proliferation of human colon adenocarcinoma cells through inhibition of ERK1/2 and cyclin D1. Mol Nutr Food Res 53:897–903
24. Park J, Ha H, Seo J et al (2004) Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Am J Transplant 4:1982–1990
25. Mesquita FS, Dyer SN, Heinrich DA et al (2010) Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol Reprod 82:341–351